(Q40707309)

22 September 2017

title

Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. (English)

1 reference

22 September 2017

1 reference

1 reference

Bingliang Lin

1

1 reference

22 September 2017

Calvin Q Pan

2

1 reference

22 September 2017

Dongying Xie

3

1 reference

22 September 2017

Junqiang Xie

4

1 reference

22 September 2017

Shibin Xie

5

1 reference

22 September 2017

Xiaohong Zhang

6

1 reference

22 September 2017

Biao Wu

7

1 reference

22 September 2017

Chaoshuang Lin

8

1 reference

22 September 2017

Zhiliang Gao

9

1 reference

22 September 2017

publication date

11 February 2013

1 reference

22 September 2017

published in

Hepatology international

1 reference

22 September 2017

volume

7

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

460-467

1 reference

https://scigraph.springernature.com/pub.10.1007/s12072-012-9415-y

22 September 2017

exact match

0 references

cites work

Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Clinical features and outcome of chronic viral hepatitis with acute exacerbation in patients with concurrent infections of hepatitis B and C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Epidemiology of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9415-Y

Antiviral therapy for hepatitis B virus associated hepatic failure.

21 January 2018

1 reference

12 December 2020

High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

12 December 2020

Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

1 reference

12 December 2020

Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B

1 reference

12 December 2020

Acute liver failure: Summary of a workshop

1 reference

12 December 2020

Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B

1 reference

12 December 2020

Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B

1 reference

12 December 2020

10.1007/S12072-012-9415-Y

Identifiers

DOI

1 reference

22 September 2017

1 reference